Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction

Clinical and Vaccine Immunology

Volumn 19, Issue 8, 2012, Pages 1126-1130

  Ishola, David A ^a,d   Borrow, Ray ^a,b   Findlow, Helen ^a   Findlow, Jamie ^a   Trotter, Caroline ^c   Ramsay, Mary E ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY;

ACTIVE IMMUNIZATION; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; HERD IMMUNITY; HUMAN; INFECTION RESISTANCE; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; REVACCINATION; SEROPREVALENCE; UNITED KINGDOM;

EID: 84864546846     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05655-11     Document Type: Article

References (25)

1. ACIP. 2011. Updated recommendations for use of meningococcal conjugate vaccines - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly. Rep. 60:72-76.
2. Balmer P, Borrow R, Miller E. 2002. Impact of meningococcal C conjugate vaccine in the UK. J. Med. Microbiol. 51:717-722.
3. Borrow R, et al. 2010. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin. Vaccine Immunol. 17:154-159.
4. Borrow R, Balmer P, Miller E. 2005. Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine 23:2222-2227. (Pubitemid 40341456)
5. Borrow R, et al. 2002. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J. Infect. Dis. 186:1353-1357. (Pubitemid 35193017)
6. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. 2010. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin. Vaccine Immunol. 17:840-847.
7. Christensen H, May M, Bowen L, Hickman M, Trotter CL. 2010. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect. Dis. 10:853-861.
8. de Voer RM, et al. 2010. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine. PLoS One 5:e12144. doi:10.1371/journal.pone. 0012144.
9. De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G. 2011. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. Pediatr. Infect. Dis. J. 30:566-569.
10. Gay NJ, Hesketh LM, Morgan-Capner P, Miller E. 1995. Interpretation of serological surveillance data for measles using mathematical models: implications for vaccine strategy. Epidemiol. Infect. 115:139-156.
11. Health Protection Agency. 2011. Laboratory confirmed cases of all invasive meningococcal disease by serogroup, age and epidemiological year, England and Wales, 2000 - 01 to 2009 -10. (Last reviewed, 2 August 2011.) http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb-C/1234859710351? printable=true. Accessed 15 September 2011.
12. Kelly H, Riddell MA, Gidding HF, Nolan T, Gilbert GL. 2002. A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia. Vaccine 20:3130-3136.
13. Maiden MC, et al. 2008. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis. 197:737-743. (Pubitemid 351364476)
14. Maiden MC, Stuart JM. 2002. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359:1829-1831.
15. Maslanka SE, et al. 1997. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin. Diagn. Lab Immunol. 4:156-167. (Pubitemid 27130227)
16. Miller E, Salisbury D, Ramsay M. 2001. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20(Suppl 1):S58-S67. (Pubitemid 32925012)
17. Osborne K, Gay N, Hesketh L, Morgan-Capner P, Miller E. 2000. Ten years of serological surveillance in England and Wales: methods, results, implications and action. Int. J. Epidemiol. 29:362-368. (Pubitemid 30209831)
18. Perrett KP, et al. 2010. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin. Infect. Dis. 50:1601-1610.
19. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. 2003. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326:365-366. (Pubitemid 36241472)
20. Snape MD, et al. 2008. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 336:1487-1491. (Pubitemid 351977021)
21. Trotter C, Borrow R, Andrews N, Miller E. 2003. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine 21:1094-1098. (Pubitemid 36139939)
22. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. 2004. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364:365-367. (Pubitemid 38970013)
23. Trotter CL, et al. 2008. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin. Vaccine Immunol. 15:1694-1698.
24. Trotter CL, McVernon J, Andrews NJ, Burrage M, Ramsay ME. 2003. Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet 361:1523-1524. (Pubitemid 36566347)
25. Trotter CL, Ramsay ME, Kaczmarski EB. 2002. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun. Dis. Public Health 5:220-225.